Search

Thiabendazole

2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential.

Artesunate

[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]

Allisartan isoproxil

Allisartan isoproxil is under investigation in clinical trial NCT03264352 (Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes).

TL-895

TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B … cell malignancies including chronic lymphocytic leukemia), NCT05280509 (recruiting, combination with Ruxolitinib in myelofibrosis), NCT04655118 (recruiting, myelofibrosis), NCT04669067 (active, not recruiting

HEPES

Ametantrone

Ametantrone is a small molecule drug. Ametantrone has a monoisotopic molecular weight of 412.21 Da.

Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen

Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)

Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen

Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen